The Patent Trial and Appeal Board has released AIA trial filing
and disposition numbers for August 2016. Filings remained near the
150 mark, with 143 total trials being requested in August, 136 of
those being requests for Inter Partes Review. This is a tick down
from 157 total filings in July and shy of the FY 2016 high of 176
in June. Projected filings for FY 2016, which ended September 30th,
are at 1668 petitions, down about 12% from 1897 filings in FY
The August trial institution rate was high at 76.3%, with 74 of
97 institution decisions resulting in PTAB trials, led by strong
results for petitioners in the Mechanical/Business Method art
(82.4% – 14 of 17) and the Electrical/Computer art (75.3%
– 55 of 73). This compared with a FY 2016 rate of 68.4% and
an overall institution rate just shy of 70% since PTAB trials were
introduced in September 2012.
Forty-four IPR Final Written Decisions were issued in August,
with 21 (47%) of those decisions cancelling all instituted claims
and a very substantial 15 decisions (34%) finding all claims not
unpatentable. This is notable, as historically, patent owners have
only been able to rescue all of the claims of a patent, once
instituted, about 15% of the time. In all, 61.8% of instituted
claims were cancelled at the end of PTAB trials in August,
significantly lower than the historic rate of 82.3%.
The full set of August 2016 PTAB statistics can be accessed here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
In Wasica Finance GmbH v. Continental Automotive Systems, Inc., No. 15-2078 (Fed. Cir. 2017), the patentee Wasica Finance discovered, among other things, the importance of using consistent terminology in the patent specification and claims.
While under attack for several years now, the patent infringement defense of laches was dealt a serious, and likely final, blow by the recent Supreme Court case of SCA Hygiene Products AB et al. v. First Quality Baby Products LLC et al.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
On April 6, 2017, the Federal Circuit reversed-in-part and affirmed-in-part the district court's judgment of infringement and summary judgment for non-infringement of The Medicines Company's ("MedCo") patents-in-suit.
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).